Dedham, Mass.– Qlaris Bio, a clinical-stage biotechnology company focused on novel therapies for glaucoma, will present new clinical and preclinical findings on its investigational drug QLS-111 at the upcoming 2025 World Glaucoma Congress, taking place June 25–28 in Honolulu, Hawaii. The data will be shared through an oral presentation and two poster sessions, showcasing QLS-111’s innovative approach to lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).
QLS-111 is a first-in-class, preservative-free topical eye drop designed to reduce IOP through a unique mechanism targeting episcleral venous pressure (EVP)—a pathway not fully addressed by existing glaucoma treatments. The drug works by opening ATP-sensitive potassium (KATP) channels and relaxing vascular tissues beyond the trabecular meshwork, including collector channels and episcleral vessels, thereby decreasing resistance in the distal outflow system.
The data to be presented include clinical results from the recently completed Phase 2 “Osprey” (QC-111-201) and “Apteryx” (QC-111-203) studies. These studies evaluated the safety and efficacy of QLS-111 in patients with POAG and OHT. Additional preclinical data featured in poster presentations will further support the drug’s novel mechanism and potential therapeutic role.
Dr. Barbara Wirostko, Chief Medical Officer of Qlaris Bio, highlighted the significance of the findings, noting that QLS-111 demonstrates strong additive IOP-lowering benefits when used alongside prostaglandin analogs like latanoprost. She emphasized the compound’s favorable safety profile, particularly at the 0.015% dose, which was not associated with added hyperemia—a common side effect in glaucoma drops. As a preservative-free formulation, QLS-111 may also improve long-term treatment adherence and patient comfort.
With current glaucoma therapies often limited by side effects or incomplete targeting of IOP pathways, QLS-111 is being positioned as a complementary option that could enhance outcomes when added to existing regimens or used as an alternative to surgical drainage devices.
Qlaris Bio’s upcoming presentations at WGC 2025 are expected to generate interest among ophthalmologists and researchers seeking new, patient-friendly solutions for IOP management in glaucoma care.
